Engineered immune cells take on tough ovarian cancer
Disease control
Recruiting now
This early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to ch…
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC